• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Neogen Announces the Appointment of New Board Member

    10/1/24 8:45:00 AM ET
    $NEOG
    $QGEN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $NEOG alert in real time by email

    LANSING, Mich., Oct. 1, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, announced today that it has appointed Thierry Bernard as a director to its Board, effective November 1, 2024.

    Neogen Corporation (PRNewsfoto/Neogen Corporation)

    "We are pleased to welcome Thierry Bernard to the Neogen Board of Directors and look forward to his guidance as the company continues in its commitment to fueling a brighter future for global food security," said Jim Borel, Neogen's Board Chair. "As a sitting CEO with a wealth of knowledge in science and technologies relevant to Neogen and its markets, we are confident that he will provide significant value to the Board during the company's continued growth." 

    Thierry Bernard is Chief Executive Officer of QIAGEN N.V. (NYSE:QGEN, Frankfurt Stock Exchange: QIA))), a leading global provider of sample-to-insight solutions that are used to transform biological materials into molecular insights. Mr. Bernard was named to the role in March 2020 after joining QIAGEN in 2015. Prior to his role at QIAGEN, Mr. Bernard spent 15 years with bioMérieux SA, where he held roles of increasing responsibility, most recently as Corporate Vice President, Global Commercial Operations, Investor Relations and the Greater China Region. He also held senior management roles in other leading international companies.

    About Neogen

    Neogen Corporation is committed to fueling a brighter future for global food security through the advancement of human and animal well-being. Harnessing the power of science and technology, Neogen has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. A world leader in these fields, Neogen has a presence in over 140 countries with a dedicated network of scientists and technical experts focused on delivering optimized products and technology for its customers.

    Contact 

    [email protected]

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/neogen-announces-the-appointment-of-new-board-member-302263825.html

    SOURCE Neogen Corporation

    Get the next $NEOG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NEOG
    $QGEN

    CompanyDatePrice TargetRatingAnalyst
    Qiagen N.V.
    $QGEN
    1/22/2026$54.00Buy → Hold
    Deutsche Bank
    Qiagen N.V.
    $QGEN
    12/11/2025$50.00Buy → Neutral
    Citigroup
    Neogen Corporation
    $NEOG
    7/29/2025Outperform → Mkt Perform
    William Blair
    Qiagen N.V.
    $QGEN
    6/24/2025$55.00Overweight
    Barclays
    Qiagen N.V.
    $QGEN
    4/4/2025Buy → Neutral
    Redburn Atlantic
    Qiagen N.V.
    $QGEN
    2/19/2025$52.00 → $42.00Outperform → Neutral
    Robert W. Baird
    Qiagen N.V.
    $QGEN
    1/6/2025$48.00Overweight → Equal-Weight
    Morgan Stanley
    Neogen Corporation
    $NEOG
    12/19/2024$15.00Buy
    Guggenheim
    More analyst ratings

    $NEOG
    $QGEN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Nassif Mikheal bought $486 worth of shares (49 units at $9.93) (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    2/2/26 4:36:07 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    CEO Nassif Mikheal bought $1,279 worth of shares (137 units at $9.33) (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    1/16/26 9:04:01 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    CEO Nassif Mikheal bought $1,106 worth of shares (177 units at $6.25) (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    11/7/25 12:20:20 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    $QGEN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Neogen Issues Voluntary Nationwide Recall of Neogen®Vet HYCOAT® Hyaluronate Sodium Sterile Solution

    Neogen Corporation (NASDAQ:NEOG) is voluntarily recalling all lots within expiry of Neogen®Vet HYCOAT® Hyaluronate Sodium Sterile Solution, for use in dogs, cats, and horses, to the veterinarian level. Neogen distributes this product, which is manufactured by a third-party supplier. This recall has been initiated due to microbial contamination in certain lots of 10 mL/50 mg product vials. Neogen received a number of reports of adverse events in horses following intraarticular injections of this product, which is inconsistent with its labeled, intended use. To date, Neogen has not received reports of adverse events when used in a manner consistent with the labeled use. While the company's

    1/28/26 6:27:00 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    QIAGEN Appoints Mark Stevenson to Supervisory Board

    QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced that Mark Stevenson has been appointed as an independent member of the Supervisory Board as of January 23, 2026, and will stand for election at the next Annual General Meeting in June 2026. In addition, Prof. Dr. Ross Levine has stepped down from the Supervisory Board also on January 23, 2026, following his appointment to a new leadership role as Chief Scientific Officer at Memorial Sloan Kettering Cancer Center. He will continue to serve as Chair of the QIAGEN Scientific Advisory Board. "We are pleased to welcome Mark Stevenson to our Supervisory Board," said Stephen H. Rusckowski, Chairman of the Supervisory Board. "Ma

    1/26/26 4:05:00 PM ET
    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    QIAGEN N.V. to Release Results for Q4 2025 and Hold Webcast

    QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the fourth quarter of 2025. Press release date / time: Wednesday, February 4 shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Thursday, February 5, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time. Three options for joining the conference call Register for call back connection - Click here: Connect me Service is available 15 minutes before the call starts Dial-in by phone U.S.: +1 646 769 9200 UK: +44 (0)20 7769 6464 GER: +49 (0)69 254 99300 Conference ID: 3382302 To avoid waiting time, please join the even

    1/19/26 9:56:00 AM ET
    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NEOG
    $QGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Nassif Mikheal bought $486 worth of shares (49 units at $9.93) (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    2/2/26 4:36:07 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: Senior Vice President Ranalli Tamara A. was granted 101,626 shares (SEC Form 4)

    4/A - NEOGEN CORP (0000711377) (Issuer)

    1/29/26 10:30:09 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Senior Vice President Ranalli Tamara A. was granted 50,813 shares (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    1/26/26 9:34:27 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    $QGEN
    SEC Filings

    View All

    Amendment: SEC Form 25-NSE/A filed by Qiagen N.V.

    25-NSE/A - QIAGEN N.V. (0001015820) (Subject)

    1/9/26 12:05:14 PM ET
    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Neogen Corporation

    10-Q - NEOGEN CORP (0000711377) (Filer)

    1/8/26 4:07:39 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 25-NSE filed by Qiagen N.V.

    25-NSE - QIAGEN N.V. (0001015820) (Subject)

    1/8/26 9:50:18 AM ET
    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NEOG
    $QGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Qiagen downgraded by Deutsche Bank with a new price target

    Deutsche Bank downgraded Qiagen from Buy to Hold and set a new price target of $54.00

    1/22/26 8:26:25 AM ET
    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Qiagen downgraded by Citigroup with a new price target

    Citigroup downgraded Qiagen from Buy to Neutral and set a new price target of $50.00

    12/11/25 8:53:31 AM ET
    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Neogen downgraded by William Blair

    William Blair downgraded Neogen from Outperform to Mkt Perform

    7/29/25 3:32:27 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    $QGEN
    Leadership Updates

    Live Leadership Updates

    View All

    QIAGEN Appoints Mark Stevenson to Supervisory Board

    QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced that Mark Stevenson has been appointed as an independent member of the Supervisory Board as of January 23, 2026, and will stand for election at the next Annual General Meeting in June 2026. In addition, Prof. Dr. Ross Levine has stepped down from the Supervisory Board also on January 23, 2026, following his appointment to a new leadership role as Chief Scientific Officer at Memorial Sloan Kettering Cancer Center. He will continue to serve as Chair of the QIAGEN Scientific Advisory Board. "We are pleased to welcome Mark Stevenson to our Supervisory Board," said Stephen H. Rusckowski, Chairman of the Supervisory Board. "Ma

    1/26/26 4:05:00 PM ET
    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million

    Return of approximately $500 million – maximum approved by shareholders – set to be completed on January 7, 2026 Capital return to be conducted through synthetic share repurchase – combines a fast direct capital repayment to shareholders with a reverse stock split that enhances EPS QIAGEN delivers well ahead of schedule on its commitment to return at least $1 billion through end-2028, considering additional ways to increase returns in 2026 and beyond QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced details for completion of plans to return approximately $500 million to shareholders through a synthetic share repurchase that combines a direct capital repayment

    12/18/25 11:27:00 AM ET
    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    QIAGEN Unveils QIAsymphony Connect and Showcases New Precision Oncology Innovations at AMP 2025

    QIAsymphony Connect, the next generation of automated nucleic acid purification platform, to be shown at AMP 2025 as early access phase begins ahead of full release in mid-2026 QIAGEN showcases Sample to Insight workflows for comprehensive genomic profiling (CGP) based on Element Biosciences Trinity™ technology Partnership with Myriad Genetics Inc. to highlight development of a homologous recombination deficiency (HRD) assay for use in cancer profiling QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced the debut of QIAsymphony Connect, the next generation of QIAGEN's widely adopted automated nucleic acid purification platform, at the 2025 AMP (Association for

    11/10/25 1:30:00 AM ET
    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NEOG
    $QGEN
    Financials

    Live finance-specific insights

    View All

    QIAGEN N.V. to Release Results for Q4 2025 and Hold Webcast

    QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the fourth quarter of 2025. Press release date / time: Wednesday, February 4 shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Thursday, February 5, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time. Three options for joining the conference call Register for call back connection - Click here: Connect me Service is available 15 minutes before the call starts Dial-in by phone U.S.: +1 646 769 9200 UK: +44 (0)20 7769 6464 GER: +49 (0)69 254 99300 Conference ID: 3382302 To avoid waiting time, please join the even

    1/19/26 9:56:00 AM ET
    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Neogen Announces Second-Quarter 2026 Results

    Revenue of $224.7 million, a decrease of 2.8% YoY; Core growth1 increased 2.9% YoY Net loss of $15.9 million; Adjusted Net Income1 of $22.6 million Adjusted EBITDA1 of $48.7 million; Adjusted EBITDA margin1 increased 470 bps sequentially Company hires key senior commercial leaders Petrifilm manufacturing transition remains on track Raising FY 2026 revenue and Adjusted EBITDA guidance 1 Non-GAAP financial measures; see explanations and reconciliations that follow Neogen Corporation (NASDAQ:NEOG) announced today the results of the second quarter ended November 30, 2025. "I am exceptionally proud of the Neogen team as we have initiated the first phase of our strategic tr

    1/8/26 7:00:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Announces Second-Quarter Earnings Release Date

    Neogen® Corporation (NASDAQ:NEOG) will issue its second-quarter earnings release before the opening of the market on January 8, 2026. Executives from the company will host a webcast and conference call later that morning, beginning at 8:00 a.m. Eastern time, to discuss the financial results. The conference call can be accessed by dialing: Toll-Free - North America: 1-800-549-8228 International: (+1) 646-564-2877 Conference ID: 82072 The live webcast can be accessed through Neogen's Investor Relations webpage, investors.neogen.com, under the "Events & Presentations" subheading. A replay of the conference call and webcast will be available shortly following the conclusion of the call and c

    12/18/25 9:00:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    $QGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Neogen Corporation

    SC 13G - NEOGEN CORP (0000711377) (Subject)

    11/14/24 4:28:12 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G filed by Neogen Corporation

    SC 13G - NEOGEN CORP (0000711377) (Subject)

    11/14/24 11:16:20 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G filed by Qiagen N.V.

    SC 13G - QIAGEN N.V. (0001015820) (Subject)

    11/8/24 10:52:38 AM ET
    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care